Stock listing

NASDAQ:ABCL AbCellera Biologics Inc. Stock

Home listing (NASDAQ) of AbCellera Biologics Inc.

Follow AbCellera Biologics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ABCL

$11.80 USD -0.88 (-6.9%)

Close on Oct 16, 2026

Since Jul 6, 2026 +49.9% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$11.72 – $12.68 USDOct 16, 2026
Volume
4.10M sharesOct 16, 2026
Market value
$3.82B USDAt the close on Oct 16, 2026 · price × 324.0M shares outstanding
AbCellera Biologics Inc. logo
Ticker
NASDAQ:ABCL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Abcellera Biologics (NASDAQ:ABCL) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 5:00 PM ET

    Watch Transcript

  • Abcellera Biologics (NASDAQ:ABCL) Q1 2026 Earnings Call

    Mon, May 11, 2026 · 5:00 PM ET

    Watch Transcript

  • Abcellera Biologics (NASDAQ:ABCL) Q4 2025 Earnings Call

    Tue, Feb 24, 2026 · 5:00 PM ET

    Watch Transcript

Latest news

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

Oct 8, 2026

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

Oct 1, 2026

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

Sep 16, 2026

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

Sep 2, 2026

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

Aug 13, 2026

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aug 11, 2026

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Aug 10, 2026

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

Aug 7, 2026

Q2 2026 Business Update Presentation

Aug 5, 2026

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

Jul 29, 2026

All AbCellera Biologics Inc. news

Financings

  • Public offering of common shares and pre-funded warrants

    Aug 13, 2026

    Update: about US$200M · US$9.75 a share · Jefferies +4

    Dealers: Jefferies (co-lead), J.P. Morgan (co-lead), Cantor (co-lead), UBS Investment Bank (co-lead), BMO Capital Markets (co-lead)

    Use of proceeds: Research, development and clinical advancement of its internal pipeline including lead program ABCL635, working capital and general corporate purposes

    Announced Aug 11, 2026 · Update Aug 13, 2026

Read by 6ix AI from the company's releases

Decks

AbCellera Biologics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 160 in all · newest Oct 8, 2026 · oldest 2020
Calls
23 calls with a replay · 23 with a transcript · latest Aug 5, 2026
Decks
35 decks · latest Aug 10, 2026

Where AbCellera Biologics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ABCL · Home listing · This pageNASDAQUnited StatesUSD
gettex:8QQgettexGermanyEUR
Tradegate:8QQTradegateGermanyEUR
LS Exchange:A2QKXSLS ExchangeGermanyEUR
BOATS:ABCLBOATSUnited StatesUSD
Lang & Schwarz:A2QKXSLang & SchwarzGermanyEUR
Frankfurt:8QQFrankfurtGermanyEUR
BX Swiss:ABCLBX SwissSwitzerlandCHF
Dusseldorf:8QQDusseldorfGermanyEUR
Hamburg:8QQHamburgGermanyEUR
Munich:8QQMunichGermanyEUR
Stuttgart:8QQStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about AbCellera Biologics Inc.